Click For Photo: https://i.dailymail.co.uk/i/newpix/2018/08/15/17/4F1DA58A00000578-0-image-a-48_1534351152133.jpg
Tens of thousands of HIV patients could soon be offered a long-lasting jab to control the killer virus and keep AIDS at bay.
Results from a landmark trial show the monthly injection is as effective as the daily cocktail of pills patients currently take.
Experts - Regimen - ART - Jab - Compliance
Experts claim replacing the daily regimen of three or more antiretroviral (ART) pills with a jab will improve compliance.
The year-long Phase III trial - the final hurdle faced before treatments can be licensed - was carried out by an Irish drug firm and involved HIV patients from 13 countries.
Charities - Adults - Children - World - HIV
Charities estimate nearly 37 million adults and children across the world have HIV, including at least 100,000 in the UK.
The lethal virus progressively damages the cells in the immune system, weakening the body's ability to fight infections.
Left - AIDS - Name - Series - Infections
Left untreated, this leads to AIDS – the collective name for a series of deadly infections which the weakened immune system cannot tackle.
The jab - which has to be administered by a nurse or doctors at present - contains two ART drugs, cabotegravir and rilpirivine.
ATLAS - Trial - Phase - III - Testing
The new ATLAS trial was a Phase III, the final testing hurdle before a new drug or treatment can be licensed for use on humans.
Nearly 620 patients with suppressed HIV from 13 countries were given a three-pill standard treatment, before switching to the monthly jab.
ViiV - Healthcare - Firm - Trial - Today
ViiV Healthcare, the pharmaceutical firm behind the trial, today claimed the injection met its primary goal of long-term viral suppression.
Effectiveness at keeping HIV suppressed was similar between the jab and the three-pill-a-day treatment over a...
Wake Up To Breaking News!